Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab.

ABSTRACT:

Background

Durvalumab is an anti-PD-L1 immune checkpoint inhibitor approved for consolidation therapy for patients with stage III non-small cell lung cancer (NSCLC) after chemoradiation. The purpose of our study was to evaluate the association between the degree of tumor PD-L1 expression and outcomes of stage III NSCLC patients treated with durvalumab.

Methods

We conducted a retrospective analysis of all the patients who received durvalumab between July 2017 and July 2019 at our facilities and were diagnosed with or progressed to stage III NSCLC before durvalumab consolidation. Patients were divided into groups based on the degree of PD-L1 expression: <1%, 1-49%, and 50-100%. Overall survival and progression-free survival were estimated by the Kaplan-Meier method and the Mul

SUBMITTER: Jazieh K 

PROVIDER: S-EPMC8350087 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature